A closely watched next-generation blood thinner being developed by Bristol Myers Squibb and Johnson & Johnson failed in one of three late-stage trials.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback